| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $37.6M | — | -38.6% |
| SG&A Expense | $8.5M | — | +54.9% |
| Operating Income | -$46.1M | — | +30.9% |
| Net Income | -$43.3M | — | +32.7% |
| EPS (Basic) | -$0.96 | — | +49.5% |
| EPS (Diluted) | -$0.96 | — | +49.5% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $62.1M | +36.4% | +24.5% |
| Short-term Investments | $264.3M | -1.1% | +109.4% |
| Current Assets | $348.7M | +4.7% | +87.7% |
| Total Assets | $349.3M | +4.8% | +62.1% |
| Current Liabilities | $25.0M | -3.7% | +93.0% |
| Total Liabilities | $25.3M |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$41.9M | — | +38.4% |
| Investing Cash Flow | $3.6M | — | -90.3% |
| Financing Cash Flow | $54.9M | — | +711.9% |
| +95.4% |
| Stockholders' Equity | $324.0M | +5.5% | +60.0% |